Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRSP Stock Forecast 2025-2026
$51.19
Current Price
$4.51B
Market Cap
Buy 17
Hold 10
Sell 1
Wall St Analyst Ratings
Distance to CRSP Price Targets
+423.5%
To High Target of $268.00
+56.3%
To Median Target of $80.00
-37.5%
To Low Target of $32.00
CRSP Price Momentum
+5.5%
1 Week Change
+22.3%
1 Month Change
-3.8%
1 Year Change
+30.1%
Year-to-Date Change
-19.6%
From 52W High of $63.68
+70.4%
From 52W Low of $30.04
📊 TOP ANALYST CALLS
Did CRSP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CRISPR is one of their latest high-conviction picks.
Latest CRSP Stock Price Targets & Analyst Predictions
Based on our analysis of 36 Wall Street analysts, CRSP has a bullish consensus with a median price target of $80.00 (ranging from $32.00 to $268.00). The overall analyst rating is Buy (7.9/10). Currently trading at $51.19, the median forecast implies a 56.3% upside. This outlook is supported by 17 Buy, 10 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Terence Flynn at Morgan Stanley, suggesting a 37.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRSP Analyst Ratings
17
Buy
10
Hold
1
Sell
CRSP Price Target Range
Low
$32.00
Average
$80.00
High
$268.00
Current: $51.19
Latest CRSP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRSP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 27, 2025 | Clear Street | Bill Maughan | Hold | Downgrade | $45.00 |
| Jun 27, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $105.00 |
| Jun 27, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $86.00 |
| Jun 27, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $65.00 |
| Jun 26, 2025 | Needham | Gil Blum | Buy | Reiterates | $81.00 |
| Jun 26, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $82.00 |
| May 21, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $86.00 |
| May 20, 2025 | Needham | Gil Blum | Buy | Reiterates | $81.00 |
| May 20, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $65.00 |
| May 9, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $42.00 |
| May 8, 2025 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $47.00 |
| May 7, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $82.00 |
| May 7, 2025 | Needham | Gil Blum | Buy | Maintains | $81.00 |
| Apr 9, 2025 | Needham | Gil Blum | Buy | Reiterates | $84.00 |
| Feb 19, 2025 | Cantor Fitzgerald | Eric Schmidt | Neutral | Reiterates | $0.00 |
| Feb 18, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $82.00 |
| Feb 14, 2025 | Evercore ISI Group | Liisa Bayko | Outperform | Upgrade | $99.00 |
| Feb 14, 2025 | Morgan Stanley | Terence Flynn | Underweight | Maintains | $32.00 |
| Feb 13, 2025 | Stifel | Benjamin Burnett | Hold | Maintains | $49.00 |
| Feb 13, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $84.00 |
Crispr Therapeutics AG (CRSP) Competitors
The following stocks are similar to CRISPR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Crispr Therapeutics AG (CRSP) Financial Data
Crispr Therapeutics AG has a market capitalization of $4.51B with a P/E ratio of -11.8x. The company generates $37.68M in trailing twelve-month revenue with a -215.0% profit margin.
Revenue growth is +71.6% quarter-over-quarter, while maintaining an operating margin of -17,158.8% and return on equity of -19.7%.
Valuation Metrics
Market Cap
$4.51B
Enterprise Value
$2.56B
P/E Ratio
-11.8x
PEG Ratio
-10.4x
Price/Sales
119.6x
Growth & Margins
Revenue Growth (YoY)
+71.6%
Gross Margin
N/A
Operating Margin
-17,158.8%
Net Margin
-215.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+42.0%
Current Ratio
15.6x
Debt/Equity
12.0x
ROE
-19.7%
ROA
-12.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Crispr Therapeutics AG (CRSP) Business Model
About Crispr Therapeutics AG
What They Do
Develops gene editing therapies using CRISPR technology.
Business Model
Crispr Therapeutics AG generates revenue by advancing CRISPR/Cas9 technology to develop innovative therapies for genetic diseases. The company collaborates with academic institutions and industry partners to bring its research to clinical trials, aiming for eventual commercialization of its therapies.
Additional Information
Crispr Therapeutics is positioned at the forefront of the biopharmaceutical industry, focusing on areas like blood disorders, cancers, and immune system conditions. Its work in personalized medicine has the potential to significantly improve patient outcomes and health on a global scale.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
393
CEO
Dr. Samarth Kulkarni Ph.D.
Country
Switzerland
IPO Year
2016
Website
www.crisprtx.comCrispr Therapeutics AG (CRSP) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51.19, representing a -1.88% change from its previous close.
Jul 07, 2025
By Zacks Equity Research
Tale of the Tape
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
Jul 07, 2025
By Zacks Equity Research
Analyst Blog
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Jun 27, 2025
By Zacks Equity Research
Fundamental Analysis
Latest News
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
7 days ago
Quick Summary
CRISPR Therapeutics (CRSP) is gaining attention from Zacks.com users, indicating potential interest and developments that could influence its stock prospects.
Why It Matters
Increased attention on CRISPR Therapeutics may signal growing investor interest, potentially affecting stock volatility and future price movements.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Phase 1 clinical data for CTX310™ shows significant dose-dependent reductions in triglycerides (up to 82%) and LDL (up to 86%), with a favorable safety profile.
Why It Matters
Promising clinical data for CTX310™ indicates potential efficacy in lowering triglycerides and LDL, which could enhance marketability and drive future revenue for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Analyst recommendations from brokerage firms can significantly impact stock prices, influencing investor decisions on buying, selling, or holding stocks.
Why It Matters
Analyst ratings can significantly sway stock prices and investor sentiment, impacting trading decisions and market trends, which may affect portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CRISPR Therapeutics AG (CRSP) closed at $46.78, up 2.7% from the previous day in the latest trading session.
Why It Matters
CRISPR Therapeutics' 2.7% gain indicates positive market sentiment, potentially reflecting investor confidence in its future prospects and performance in the biotech sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
The Best Stocks to Invest $1,000 in Right Now
14 days ago
Quick Summary
Investors may find it challenging to select new stocks for their portfolios at this time.
Why It Matters
The uncertainty in reloading portfolios signals potential volatility or market challenges, prompting investors to reassess strategies and risk exposure.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
CRSP leads NTLA with the only approved CRISPR therapy, a broader pipeline, and recent stock gains, indicating a competitive position in the biotech sector.
Why It Matters
CRSP's approval of a CRISPR therapy and robust pipeline indicate competitive advantage and growth potential, enhancing investor confidence and potentially driving stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CRSP Stock
What is Crispr Therapeutics AG's (CRSP) stock forecast for 2026?
Based on our analysis of 36 Wall Street analysts, Crispr Therapeutics AG (CRSP) has a median price target of $80.00. The highest price target is $268.00 and the lowest is $32.00.
Is CRSP stock a good investment in 2026?
According to current analyst ratings, CRSP has 17 Buy ratings, 10 Hold ratings, and 1 Sell ratings. The stock is currently trading at $51.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRSP stock?
Wall Street analysts predict CRSP stock could reach $80.00 in the next 12 months. This represents a 56.3% increase from the current price of $51.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Crispr Therapeutics AG's business model?
Crispr Therapeutics AG generates revenue by advancing CRISPR/Cas9 technology to develop innovative therapies for genetic diseases. The company collaborates with academic institutions and industry partners to bring its research to clinical trials, aiming for eventual commercialization of its therapies.
What is the highest forecasted price for CRSP Crispr Therapeutics AG?
The highest price target for CRSP is $268.00 from at , which represents a 423.5% increase from the current price of $51.19.
What is the lowest forecasted price for CRSP Crispr Therapeutics AG?
The lowest price target for CRSP is $32.00 from Terence Flynn at Morgan Stanley, which represents a -37.5% decrease from the current price of $51.19.
What is the overall CRSP consensus from analysts for Crispr Therapeutics AG?
The overall analyst consensus for CRSP is bullish. Out of 36 Wall Street analysts, 17 rate it as Buy, 10 as Hold, and 1 as Sell, with a median price target of $80.00.
How accurate are CRSP stock price projections?
Stock price projections, including those for Crispr Therapeutics AG, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 4:45 AM UTC